FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> GlobeImmune | Gilead

Gilead, GlobeImmune team up on HBV vaccines

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Gilead Sciences ($GILD) is giving GlobeImmune an undisclosed upfront payment for early development and funding to support continued development of its hepatitis B virus (HBV) therapeutic vaccine program. The two developers have inked a worldwide license and collaboration agreement for vaccine products for use in conjunction with Gilead's Viread, which is indicated to treat HIV/AIDS, and other oral therapies for the treatment of chronic HBV infection. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about GlobeImmune   Gilead